The Non-Malignant Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2019 | HOPE for sickle cell: promising data for voxelotor
Jo Howard from Guy’s and St Thomas’ NHS Foundation Trust, London, UK, presents the results from the randomized, placebo-controlled, Phase III Hemoglobin Oxygen Affinity Modulation to Inhibit HbS PolymErization (HOPE; NCT03036813) trial of voxelotor in adults and adolescents with sickle cell disease. The data show a significant improvement in anemia and hemolysis in this patient group, indicating that voxelotor has the potential to prevent chronic organ damage. This press briefing was recorded at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.
